Deals
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
The two pharmaceutical companies are going public and anticipate raising more than $250 million to advance research and development programs and support their business initiatives.
Here’s the scoop on IPO versus SPAC (Special Purpose Acquisition Corporation) from Paul Mieyal, life sciences investment guru.
The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.
Boston-based ABclonal Biotechnology acquired contract research organization (CRO) Yurogen Biosystems.
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.